Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Hematology›Clinical Question·Updated Jul 4, 2026·v1

preferred anticoagulant for acute pulmonary embolism [Grok-4.3]

Direct oral anticoagulants are preferred to vitamin K antagonists for primary treatment of acute pulmonary embolism in adults. The American Society of Hematology conditionally recommends direct oral anticoagulants over vitamin K antagonists [1]. In one randomized trial, [[apixaban]] produced lower clinically relevant bleeding than [[rivaroxaban]]

Moderate Evidence22 references·1,185 words·5 min read·v1
Direct oral anticoagulants are preferred to vitamin K antagonists for primary treatment of acute pulmonary embolism in adults. The American Society of Hematology conditionally recommends direct oral anticoagulants over vitamin K antagonists [1].

Board Review — High Yield

  • •ASH guidelines conditionally recommend direct oral anticoagulants over vitamin K antagonists for acute VTE [1]
  • •Apixaban produced lower clinically relevant bleeding than rivaroxaban in acute VTE using the labeled 3-month regimens [3].
  • •Apixaban lowered clinically relevant bleeding versus rivaroxaban (RR 0.46) in the three-month COBRRA trial of acute VTE [3].
  • •Apixaban shows lower clinically relevant bleeding than rivaroxaban in acute VTE populations enrolled in head-to-head trials [3].
  • •ONCO PE supports 18-month over 6-month rivaroxaban for cancer patients with low-risk PE to cut recurrent VTE [15].

Deep Dive — Evidence Details

References

  1. [1]

    Ortel TL, Neumann I, Ageno W et al.. “American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.” Blood advances (2020). PMID: 33007077 ↗

    L2GUIDELINECited in: Bottom Line
  2. [2]

    Kearon C, Akl EA, Comerota AJ et al.. “Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest (2012). PMID: 22315268 ↗

    L2GUIDELINECited in: Bottom Line
  3. [3]

    Castellucci LA, Chen VM, Kovacs MJ et al.. “Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.” The New England journal of medicine (2026). PMID: 41812192 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  4. [4]

    Lookstein RA, Konstantinides SV, Weinberg I et al.. “Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial.” Circulation (2025). PMID: 41183181 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  5. [5]

    Alam U, Ali MA, Ansab M et al.. “Extended reduced versus full-dose treatment with factor Xa inhibitors in patients with venous thromboembolism: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.” Naunyn-Schmiedeberg's archives of pharmacology (2025). PMID: 40694093 ↗

    L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  6. [6]

    Mousavi A, Shojaei S, Rahmati S et al.. “Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin in Patients With Cancer-Associated Thrombosis: A Meta-Analysis of Randomized Controlled Trials.” The American journal of cardiology (2025). PMID: 40578592 ↗

    L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  7. [7]

    Mahé I, Carrier M, Mayeur D et al.. “Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.” The New England journal of medicine (2025). PMID: 40162636 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  8. [8]

    Zeng R, Chang H, Feng G et al.. “Intermittent Pneumatic Compression to Prevent Venous Thromboembolism in Critically Ill Adult Patients.” American journal of critical care : an official publication, American Association of Critical-Care Nurses (2026). PMID: 41763891 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  9. [9]

    Husseiny YM, Ramadan S, El-Helbawy A et al.. “Mechanical Thrombectomy Versus Conventional Anticoagulants Alone in Treatment of Pulmonary Embolism: A Systematic Review and Meta-Analysis.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 41363677 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  10. [10]

    Guarascio M, Valeriani E, Girardi L et al.. “Anticoagulant treatment for isolated distal deep vein thrombosis: a systematic review and meta-analysis.” Haematologica (2025). PMID: 40400471 ↗

    L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
  11. [11]

    Dore M, Duffy R. “Outcomes of Acute PE Treated With DOACs in the Veterans Affairs Health System: A Retrospective Cohort Study.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 42313763 ↗

    L3COHORTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  12. [12]

    Kou R, Mallick R, Brown C et al.. “Anticoagulation management and outcomes in patients with cancer-associated small venous thromboembolism: a retrospective cohort study.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41791657 ↗

    L3COHORTCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  13. [13]

    Wang C, Fang P, Zhou D et al.. “Multi-center Randomized Controlled Trial of Catheter-Directed Mechanical Thrombectomy Versus Systemic Thrombolysis in Patients with Acute Intermediate-to-High-Risk Pulmonary Embolism: Study Protocol.” Cardiovascular and interventional radiology (2026). PMID: 42056311 ↗

    L2TRIAL_NONRANDOMCited in: Current Evidence and Standard
  14. [14]

    Nicoletto M, Maino A, Guarascio M et al.. “Anticoagulation therapy vs clinical surveillance in isolated subsegmental pulmonary embolism: a systematic review and meta-analysis.” Thrombosis research (2026). PMID: 41962426 ↗

    L2SR_OBSCited in: Current Evidence and Standard
  15. [15]

    Yamashita Y, Morimoto T, Muraoka N et al.. “Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).” Circulation (2024). PMID: 39556015 ↗

    L1RCTCited in: On the Horizon
  16. [16]

    Chatani R, Yamashita Y, Morimoto T et al.. “Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism　- A Predetermined Companion Report From the ONCO PE Trial.” Circulation journal : official journal of the Japanese Circulation Society (2024). PMID: 38462535 ↗

    L1RCTCited in: On the Horizon
  17. [17]

    Sartori M, Iotti M, Camporese G et al.. “Six-week low-molecular-weight heparin versus 12-week warfarin for calf deep vein thrombosis: A randomized, prospective, open-label study.” American journal of hematology (2024). PMID: 38375893 ↗

    L1RCTCited in: On the Horizon
  18. [18]

    Sista AK, Troxel AB, Tarpey T et al.. “Rationale and design of the PE-TRACT trial: A multicenter randomized trial to evaluate catheter-directed therapy for the treatment of intermediate-risk pulmonary embolism.” American heart journal (2024). PMID: 39638275 ↗

    L2TRIAL_NONRANDOMCited in: On the Horizon
  19. [19]

    Lasserson D, Gaddu P, Mehta S et al.. “Stopping anticoagulation for isolated or incidental pulmonary embolism: the STOPAPE RCT protocol.” Health technology assessment (Winchester, England) (2024). PMID: 38970429 ↗

    L2TRIAL_NONRANDOMCited in: On the Horizon
  20. [20]

    Singh M, Balmaceno-Criss M, Liu J et al.. “Chronic Anticoagulation in Patients Who Have Atrial Fibrillation Undergoing Outpatient Total Knee Arthroplasty: A Retrospective Matched Cohort Study.” The Journal of arthroplasty (2024). PMID: 39357687 ↗

    L3COHORTCited in: On the Horizon
  21. [21]

    Chong LT, Hu S, Guo TT et al.. “Direct oral anticoagulants in the treatment of chronic thromboembolic pulmonary hypertension patients: A retrospective cohort study.” Respiratory medicine (2024). PMID: 38936635 ↗

    L3COHORTCited in: On the Horizon
  22. [22]

    Su Y, Zou D, Liu Y et al.. “Anticoagulant Impact on Clinical Outcomes of Pulmonary Embolism Compared With Thrombolytic Therapy; Meta-Analysis.” Clinical cardiology (2024). PMID: 39267429 ↗

    L2SR_OBSCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…